Submit

Login Login

Register Register

Home / Journals / OR / Online First / doi:10.32604/or.2024.050161
Journal Menu
Special Issues
Table of Content

All issues

Online First

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

Past Issues

Open Access

ARTICLE

Genetic signatures of ERCC1 and ERCC2 expression, along with SNPs variants, unveil favorable prognosis in SCLC patients undergoing platinum-based chemotherapy

ENRICO CALIMAN1,2, SARA FANCELLI1,2, FEDERICO SCOLARI3, ADRIANO PASQUI4, CLARA MANNESCHI4, DANIELE LAVACCHI1, FRANCESCA MAZZONI4, FRANCESCA GENSINI5, VALERIA PASINI6, CAMILLA EVA COMIN2,7, LUCA VOLTOLINI2,8, SERENA PILLOZZI1,2,*, LORENZO ANTONUZZO1,2,4
1 Clinical Oncology Unit, Careggi University Hospital, Florence, 50134, Italy
2 Department of Experimental and Clinical Medicine, University of Florence, Florence, 50134, Italy
3 Department of Health Sciences, University of Florence, Florence, 50134, Italy
4 Medical Oncology Unit, Careggi University Hospital, Florence, 50134, Italy
5 Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Florence, 50134, Italy
6 Section of Anatomic Pathology, Department of Health Sciences, University of Florence, Florence, 50139, Italy
7 Section of Surgery, Histopathology and Molecular Pathology, University of Florence, Florence, 50139, Italy
8 Thoracic Surgery Unit, Careggi University Hospital, Florence, 50134, Italy
* Corresponding Author: SERENA PILLOZZI. Email: email
(This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)

Oncology Research https://doi.org/10.32604/or.2024.050161

Received 29 January 2024; Accepted 15 May 2024; Published online 28 June 2024

Abstract

Background: Platinum chemotherapy (CT) remains the backbone of systemic therapy for patients with small-cell lung cancer (SCLC). The nucleotide excision repair (NER) pathway plays a central role in the repair of the DNA damage exerted by platinum agents. Alteration in this repair mechanism may affect patients’ survival. Materials and Methods: We conducted a retrospective analysis of data from 38 patients with extensive disease (ED)-SCLC who underwent platinum-CT at the Clinical Oncology Unit, Careggi University Hospital, Florence (Italy), from 2015 to 2020. mRNA expression analysis and single nucleotide polymorphism (SNP) characterization of three NER pathway genes—namely ERCC1, ERCC2, and ERCC5—were performed on patient tumor samples. Results: Overall, elevated expression of ERCC genes was observed in SCLC patients compared to healthy controls. Patients with low ERCC1 and ERCC5 expression levels exhibited a better median progression-free survival (mPFS = 7.1 vs. 4.9 months, p = 0.39 for ERCC1 and mPFS = 6.9 vs. 4.8 months, p = 0.093 for ERCC5) and overall survival (mOS = 8.7 vs. 6.0 months, p = 0.4 for ERCC1 and mOS = 7.2 vs. 6.2 months, p = 0.13 for ERCC5). Genotyping analysis of five SNPs of ERCC genes showed a longer survival in patients harboring the wild-type genotype or the heterozygous variant of the ERCC1 rs11615 SNP (p = 0.24 for PFS and p = 0.14 for OS) and of the rs13181 and rs1799793 ERCC2 SNPs (p = 0.43 and p = 0.26 for PFS and p = 0.21 and p = 0.16 for OS, respectively) compared to patients with homozygous mutant genotypes. Conclusions: The comprehensive analysis of ERCC gene expression and SNP variants appears to identify patients who derive greater survival benefits from platinum-CT.

Keywords

Small cell lung cancer (SCLC); Nucleotide excision repair (NER) pathway; ERCC genes; Single nucleotide polymorphisms (SNPs); Platinum-chemotherapy (CT)

  • 479

    View

  • 59

    Download

  • 0

    Like

Related articles
Copyright© 2024 Tech Science Press
© 1997-2024 TSP (Henderson, USA) unless otherwise stated

Share Link